{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T21:10:33Z","timestamp":1786396233135,"version":"build-2736575974"},"reference-count":35,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    This first\u2010in\u2010human study investigated the safety, pharmacokinetics, and pharmacodynamics of the long\u2010acting fibroblast growth factor 21 (FGF21) analog zalfermin. Healthy male participants (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200956) with body mass index 25.0\u201334.9\u2009kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    were randomized to single ascending doses (2, 6, 12, 24, 48, 96, and 180\u2009mg) of subcutaneous zalfermin or placebo. In a second study, a single dose of 12, 30, or 96\u2009mg was administered to Japanese (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200924) and non\u2010Asian (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200918) healthy males to confirm a consistent safety and pharmacokinetic profile across ethnicity. Overall, 98 participants were enrolled across both studies and followed for 36\u2009days. Blood samples were obtained for safety and for pharmacokinetic and pharmacodynamic assessments. The primary endpoint for both studies was the number of adverse events from treatment initiation to the end of follow\u2010up, which was greater in the highest zalfermin dose cohorts in both studies. Adverse events were non\u2010serious, mainly gastrointestinal\u2010related, and mostly mild to moderate in severity; no deaths occurred. In both studies, dose proportionality was established for maximum serum concentration and area under the curve from time 0 to infinity. Time to maximum serum concentration ranged from 24 to 54\u2009h. The serum half\u2010life of zalfermin was ~120\u2009h in both studies, compatible with once\u2010weekly dosing. Significant improvements in plasma lipids were observed. Zalfermin had an acceptable safety profile across all single ascending doses, consistent with the FGF21 class. Further investigations into multiple ascending doses of zalfermin and treatment duration are warranted to assess the potential treatment of steatohepatitis and cardiometabolic disease.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial Registration:<\/jats:bold>\n                    ClinicalTrials.gov (NCT03015207 and NCT04722653)\n                  <\/jats:p>","DOI":"10.1111\/cts.70435","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T06:35:32Z","timestamp":1765002932000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Long\u2010Acting FGF21 Analog Zalfermin"],"prefix":"10.1111","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5063-1554","authenticated-orcid":false,"given":"Kirsten","family":"Dahl","sequence":"first","affiliation":[{"name":"Novo Nordisk A\/S  Bagsv\u00e6rd Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin Haljeta","family":"Friedrichsen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  Bagsv\u00e6rd Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Ribel\u2010Madsen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  Bagsv\u00e6rd Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob Schi\u00f8ler","family":"Hansen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  Bagsv\u00e6rd Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper Ole","family":"Clausen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  Bagsv\u00e6rd Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Axelsen","sequence":"additional","affiliation":[{"name":"Gubra A\/S  H\u00f8rsholm Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7127-2861","authenticated-orcid":false,"given":"Mads Sundby","family":"Palle","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  Bagsv\u00e6rd Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solvej Lund","family":"Lippert","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  Bagsv\u00e6rd Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olle","family":"Bj\u00f6rkdahl","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  Bagsv\u00e6rd Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Toubro","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  Bagsv\u00e6rd Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Key","sequence":"additional","affiliation":[{"name":"ICON Early Phase Service  San Antonio Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Andersen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  Bagsv\u00e6rd Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1514009"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015473"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15016"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.08.020"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000"},{"key":"e_1_2_9_9_1","unstructured":"FDA \u201cFDA Approves First Treatment for Patients With Liver Scarring Due to Fatty Liver Disease \u201d (2024) accessed 20 February 2024 https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010first\u2010treatment\u2010patients\u2010liver\u2010scarring\u2010due\u2010fatty\u2010liver\u2010disease."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00101.2017"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c00391"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0152"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.01.004"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02427-z"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2013.08.005"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100057"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304286"},{"key":"e_1_2_9_18_1","unstructured":"US Food and Drug Administration \u201cGuidance for Industry: Bioanalytical Method Validation \u201d (2018)."},{"key":"e_1_2_9_19_1","unstructured":"European Medicines Agency \u201cGuideline on Bioanalytical Method Validation. EMEA\/CHMP\/EWP\/192217\/2009 Rev. 1 Corr. 2** \u201d (2011)."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12676"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00347-8"},{"issue":"1","key":"e_1_2_9_22_1","first-page":"S665","article-title":"Pharmacokinetic (PK) and Pharmacodynamics (PD) of BIO89\u2010100, a Novel glycoPEGylated FGF21, in Non\u2010Alcoholic Steatohepatitis (NASH) Patients With Compensated Cirrhosis","volume":"77","author":"Alkhouri N.","year":"2022","journal-title":"Journal of Hepatology"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22344"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab624"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01425-3"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202182"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.034"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.123.001618"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-012-0739-z"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00155"},{"key":"e_1_2_9_31_1","volume-title":"Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non\u2010Alcoholic Steatohepatitis (NASH)","author":"ClinicalTrials.gov","year":"2021"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14863"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2070473"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100563"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-0879-2968"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.04.054"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70435","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T23:21:57Z","timestamp":1766704917000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/cts.70435"],"URL":"https:\/\/doi.org\/10.1111\/cts.70435","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-07-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70435"}}